Back to Authors

Fujita, Kenji P.

https://orcid.org/0000-0003-4320-7557

A5036695794 | I145311141

Mayo Clinic

Alnylam Pharmaceuticals (United States)

Citations 5

12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: B8-B8

10.1681/asn.20203110s1b8c

ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1)

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 515-515

10.1681/asn.20203110s1515a

Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (1780)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1780

Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1494

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

New England Journal of Medicine | May 3, 2019 | Volume: 381 | Issue: 7 | Pages: 614-625

10.1056/nejmoa1900866 | PMID 31050279